Wells Fargo & Company Chemo Centryx, Inc. Transaction History

Wells Fargo & Company

$434 Billion
Q3 2024

Shares

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 14, 2022	SELL	$22.17 - $51.8 $25,650 - $59,932	-1,157 Reduced 24.83%	3,502 $181,000
Q2 2022 Aug 12, 2022	SELL	$15.36 - $27.51 $313,774 - $561,974	-20,428 Reduced 81.43%	4,659 $115,000
Q1 2022 May 16, 2022	SELL	$22.22 - $39.12 $1.15 Million - $2.03 Million	-51,958 Reduced 67.44%	25,087 $629,000
Q4 2021 Feb 14, 2022	SELL	$18.38 - $40.5 $5.21 Million - $11.5 Million	-283,524 Reduced 78.63%	77,045 $2.81 Million
Q3 2021 Nov 15, 2021	BUY	$13.18 - $19.83 $3 Million - $4.52 Million	227,884 Added 171.75%	360,569 $6.17 Million
Q2 2021 Aug 16, 2021	SELL	$9.59 - $50.88 $1.29 Million - $6.83 Million	-134,187 Reduced 50.28%	132,685 $1.78 Million
Q1 2021 May 13, 2021	BUY	$49.53 - $68.4 $432,743 - $597,610	8,737 Added 3.38%	266,872 $13.7 Million
Q4 2020 Feb 09, 2021	BUY	$47.25 - $65.16 $75,883 - $104,646	1,606 Added 0.63%	258,135 $16 Million
Q3 2020 Nov 05, 2020	BUY	$46.35 - $61.69 $5.5 Million - $7.32 Million	118,577 Added 85.96%	256,529 $14.1 Million
Q2 2020 Aug 13, 2020	BUY	$38.58 - $65.07 $3.97 Million - $6.69 Million	102,843 Added 292.92%	137,952 $7.94 Million
Q1 2020 May 14, 2020	BUY	$32.73 - $50.78 $1.15 Million - $1.78 Million	35,109 New	35,109 $1.41 Million

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.